![Duane Burnett](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
Duane Burnett is the founder of Arkuda Therapeutics, Inc., where he holds the title of Chief Technology Officer since 2018.
He is currently working as a Director at Aquinnah Pharmaceuticals, Inc.
Posizioni attive di Duane Burnett
Società | Posizione | Inizio |
---|---|---|
Aquinnah Pharmaceuticals, Inc.
![]() Aquinnah Pharmaceuticals, Inc. BiotechnologyHealth Technology Aquinnah Pharmaceuticals, Inc. restores the health of people with ALS, Alzheimer?s disease and other neurodegenerative diseases. The company was founded by Glenn Larsen and Ben Wolozin in 2014 and is headquartered in Cambridge, MA. | Direttore/Membro del Consiglio | - |
Arkuda Therapeutics, Inc.
![]() Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA. | Fondatore | 01/01/2018 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Aquinnah Pharmaceuticals, Inc.
![]() Aquinnah Pharmaceuticals, Inc. BiotechnologyHealth Technology Aquinnah Pharmaceuticals, Inc. restores the health of people with ALS, Alzheimer?s disease and other neurodegenerative diseases. The company was founded by Glenn Larsen and Ben Wolozin in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Arkuda Therapeutics, Inc.
![]() Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Duane Burnett